A phase I study of RGD-AAVP-TNF

Trial Profile

A phase I study of RGD-AAVP-TNF

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs RGD-AAVP-TNF (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 04 Mar 2017 New trial record
    • 09 Feb 2017 According to an AAVP Biosystems media release, the company is preparing to submit its IND application in 2017, and initiate its first in-human Phase I clinical study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top